Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial

Michael Braun(Peter MacCallum Cancer Centre), Michel Seymour(University of Leeds), Susan D. Richman(University of Leeds), Lindsay C Thompson(MRC Clinical Trials Unit at UCL), James M. Allan(University of York), Philip Quirke(University of Leeds), Angela Meade(Medical Research Council), Mahesh Parmar(University College London), Catherine Daly(University of Leeds), Julian Adlard(Chapel Allerton Hospital)
Journal of Clinical Oncology
October 27, 2009
10.1200/jco.2008.21.6283
Cited by 128

Related Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k